The FDA has granted accelerated approval to Bristol Myers Squibb's iberdomide, marketed as Zenbexus, for relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab. As a first-in-class CELMoD agent, iberdomide is a cereblon-modulating peptide-like molecule that induces targeted protein degradation to eliminate cancer-driving proteins. The approval was supported by Phase 3 data showing a statistically significant improvement in minimal residual disease-negative complete response rates compared to standard care.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.